105 related articles for article (PubMed ID: 9267101)
41. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
42. Drug interactions with the taxanes.
Baker SD
Pharmacotherapy; 1997; 17(5 Pt 2):126S-132S. PubMed ID: 9322879
[TBL] [Abstract][Full Text] [Related]
43. Treatment of patients resistant to anthracycline therapy.
Ravdin PM
Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
[TBL] [Abstract][Full Text] [Related]
44. Taxoids: a new class of cytotoxic agents.
Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
[TBL] [Abstract][Full Text] [Related]
45. [Choice of first-line chemotherapy for advanced ovarian cancer].
Tiuliandin SA
Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
[No Abstract] [Full Text] [Related]
46. Weekly schedules of docetaxel.
Burris H
Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
[TBL] [Abstract][Full Text] [Related]
47. Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Partridge A; Winer E
Clin Breast Cancer; 2000 Jul; 1(2):164-5. PubMed ID: 11899655
[No Abstract] [Full Text] [Related]
48. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
49. [Cancer of the ovary. New therapeutic approaches].
Pujade-Lauraine E
Presse Med; 1994 Jan; 23(2):67-8. PubMed ID: 7511243
[No Abstract] [Full Text] [Related]
50. [Taxans in the treatment of ovarian cancer].
Tuxen MK; Dombernowsky P
Ugeskr Laeger; 1996 Jul; 158(27):3951-2. PubMed ID: 8701514
[No Abstract] [Full Text] [Related]
51. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
52. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
53. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
54. [Advance through research].
Internist (Berl); 1994 Aug; 35(8 Suppl):1-8. PubMed ID: 9211666
[No Abstract] [Full Text] [Related]
55. Predictive cancer genomics--what do we need?
Brenton JD; Caldas C
Lancet; 2003 Aug; 362(9381):340-1. PubMed ID: 12907001
[No Abstract] [Full Text] [Related]
56. [Current therapeutic methods in onco-hematology].
Madelaine-Chambrin I; Piquet-Sevrin V; Faure P
Ann Pharm Fr; 1996; 54(2):73-6. PubMed ID: 8734332
[TBL] [Abstract][Full Text] [Related]
57. New form of paclitaxel shows promise.
Garfield D
Lancet Oncol; 2001 Apr; 2(4):192. PubMed ID: 11905759
[No Abstract] [Full Text] [Related]
58. Cancer treatments rationed by authority.
Halle M
BMJ; 1996 Sep; 313(7060):774. PubMed ID: 8842067
[No Abstract] [Full Text] [Related]
59. Bypassing multidrug resistance in cancer cells with biodegradable polymer capsules.
Yan Y; Ochs CJ; Such GK; Heath JK; Nice EC; Caruso F
Adv Mater; 2010 Dec; 22(47):5398-403. PubMed ID: 20976679
[No Abstract] [Full Text] [Related]
60. Antitumor antibiotics and interleukin-2: a prediction.
Greentree LB
South Med J; 1988 Mar; 81(3):291-2. PubMed ID: 3258075
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
